Advanced CML: therapeutic options for patients in accelerated and blast phases.

作者: Neil P Shah

DOI:

关键词: MyelogenousOncologyLeukemiaMedicineTransplantationTyrosine-kinase inhibitorChronic myelogenous leukemiaInternal medicineNilotinibDasatinibImatinib

摘要: Tyrosine kinase inhibitor (TKI) therapy has impacted the natural course of chronic myelogenous leukemia (CML), because patients diagnosed as having chronic-phase disease can experience long-lasting responses. However, for with advanced CML (accelerated and blast phases), efficacy all current therapies is reduced. For these patients, allogeneic stem cell transplantation remains preferred treatment if a donor available, although TKIs play valuable role bridging therapy. accelerated-phase CML, imatinib, dasatinib, nilotinib have been shown to produce meaningful rates hematologic cytogenetic response. Imatinib dasatinib are also approved blast-phase CML. Studies newer agents involved heavily pretreated patients; however, response at least comparable those achieved imatinib in previous studies. Therefore, newer, more potent will probably be likely induce deep previously untreated patients. Moreover, fewer mechanisms appear exist secondary resistance nilotinib, reducing potential escape TKI therapy, may result improved longer-term outcomes. BCR-ABL-independent pathways become important, indicating that other therapeutic targets future managing

参考文章(0)